transmembrane protein 108Genealiases: CT124 · RTLN
Q-omics provides the consensus-scored TMEM108 profile across patient tissues and cancer cell-line models. TMEM108 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM108 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, TMEM108 RNA expression shows 17,583 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, BLCA, and THYM as cancer lineages where TMEM108 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM108 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM108 survival associations across molecular data types. TMEM108 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM108 RNA expression–survival associations across cancer types. High TMEM108 expression shows unfavorable associations in KIRP, UVM, LUSC, STAD and BLCA, but favorable associations in PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM108 RNA expression.
This table summarizes TMEM108 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM108. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM108 shows lower tumor expression in BLCA, COAD, LUAD and LUSC and higher tumor expression in LIHC and THCA. The BLCA box plot shows higher TMEM108 RNA expression in normal versus tumor tissue (log2 FC = −1.686, t-test p < 0.001).
This table shows molecular features associated with TMEM108 in patient tissues and cancer cell lines. In patient samples, TMEM108 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM108 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
